The purpose of the Center for Medicinal Cannabis Research is to coordinate rigorous scientific studies to assess the safety and efficacy of cannabis and cannabis compounds for treating medical conditions.
2017 National Academies Report
CMCR Legislative Report
2000 IOM Report
Megan Tevrizian, NBC7 San Diego, August 7, 2018
A California company may have developed a game changer for detecting impaired drivers.
The company Hound Labs created a breathalyzer able to detect the amount of THC in a driver's breath.
“It’s an incredibly challenging scientific problem to ensure the really, really low concentrations,” said Hound Labs CEO Mike Lynn.
“We’re talking parts per trillion in your breath,” Lynn said.
The device uses the breath to measure THC, the psychoactive chemical in pot that makes you high.
Lesley McClurg, KQED, August 6, 2018
The first prescription medication extracted from the marijuana plant is poised to land on pharmacists' shelves this fall. Epidiolex, made from purified cannabidiol, or CBD, a compound found in the cannabis plant, is approved for two rare types of epilepsy.
Its journey to market was driven forward by one family's quest to find a treatment for their son's epilepsy.
Scientific and public interest in CBD had been percolating for several years before the Food and Drug Administration finally approved Epidiolex in June. But CBD — which doesn't cause the mind-altering high that comes from THC, the primary psychoactive component of marijuana — was hard to study, because of tight restrictions on using cannabis in research.
Brooke Staggs, Orange County Register, August 1, 2018
The legalization of recreational cannabis raises new opportunities, and challenges, in addressing the health and safety effects of cannabis use.
After decades of disconnect between federal officials who consider cannabis a harmful drug and public opinion that increasingly views cannabis as something that should be legal and is potentially good medicine, the landscape on marijuana research might be shifting.
This week, UC Irvine announced it received a $9 million grant from the National Institute on Drug Abuse to study how long-term cannabis exposure affects young people’s brains.
California regulators also are setting up a process to award $10 million by summer 2019 — and $10 million more each year for the next decade — for universities to study the impacts of marijuana legalization.
And a bill recently proposed in Congress would apply the new California research model across the country, allowing scientists to gather data and study the effects of cannabis legalization nationwide for a decade.
Read the rest of the article here
Igor Grant, MD
Introduction/Overview
CMCR Symposium, June 2018
Daniele Piomelli, MD, PhD, PharmD
The health impact of cannabis
CMCR Symposium, June 2018
Ziva Cooper, PhD
Therapeutic potential of cannabis for pain alone and as an adjunct to opioids
CMCR Symposium, June 2018
Iain McGregor, PhD
Medicinal cannabis research down under: Introducing the Lambert Initiative for Cannabinoid Therapeutics
CMCR Symposium, June 2018
Thomas Marcotte, PhD
Cannabis and public safety: The challenge of cannabis-impaired driving
CMCR Symposium, June 2018